Mark C Reynolds

US Patent:

6667318, Dec 23, 2003

Filed:

Nov 26, 2001

Appl. No.:

09/994546

Inventors:

Daniel J. Burdick - Burlingame CA
Mark S. Stanley - Pacifica CA
David Oare - Belmont CA
Mark E. Reynolds - Millbrae CA
Thomas R. Gadek - Oakland CA
James C. Marsters - Oakland CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 314525

US Classification:

514326, 546214, 548182, 548200, 548517, 549473, 514365, 514369, 514422

Abstract:

The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.

US Patent:

6706753, Mar 16, 2004

Filed:

Dec 6, 2002

Appl. No.:

10/313147

Inventors:

Dean R. Artis - Kensington CA
David Y. Jackson - San Bruno CA
Thomas E. Rawson - Mountain View CA
Mark E. Reynolds - Millbrae CA
Daniel P. Sutherlin - South San Francisco CA
Mark S. Stanley - Pacifica CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 314025

US Classification:

514422, 548517, 548537, 548538, 514423

Abstract:

Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R to R , m and n are as defined herein. Compounds of the invention bind to integrin receptors and thereby inhibit binding of ligands for integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with integrins or their ligands.

US Patent:

6872735, Mar 29, 2005

Filed:

Jul 11, 2003

Appl. No.:

10/618178

Inventors:

Daniel J. Burdick - Burlingame CA, US
Mark S. Stanley - Pacifica CA, US
David Oare - Belmont CA, US
Mark E. Reynolds - Millbrae CA, US
Thomas R. Gadek - Oakland CA, US
James C. Marsters - Oakland CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K031/4525
C07D405/12

US Classification:

514326, 546214, 546225, 548200, 548517, 548537, 514330, 514365, 514422, 514423

Abstract:

The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and Rare as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.

US Patent:

6933314, Aug 23, 2005

Filed:

Sep 30, 2003

Appl. No.:

10/676706

Inventors:

Dean R. Artis - Kensington CA, US
David Y. Jackson - San Bruno CA, US
Thomas E. Rawson - Mountain View CA, US
Mark E. Reynolds - Millbrae CA, US
Daniel P. Sutherlin - South San Francisco CA, US
Mark S. Stanley - Pacifica CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K031/403
C07D209/82

US Classification:

514411, 548440, 548444

Abstract:

Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, Rto R, m and n are as defined herein. Compounds of the invention bind to αintegrin receptors and thereby inhibit binding of ligands for αintegrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with αintegrins or their ligands.

US Patent:

7101851, Sep 5, 2006

Filed:

Sep 26, 2001

Appl. No.:

10/381112

Inventors:

Henry B. Lowman - El Granada CA, US
Gerald R. Nakamura - San Francisco CA, US
Mark E. Reynolds - Millbrae CA, US
Melissa A. Starovasnik - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 38/03
A61K 38/16
C07K 4/00
C07K 14/00

US Classification:

514 12, 436513, 514 13, 514 14, 530324, 530325, 530326

Abstract:

The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated FcεRI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.

US Patent:

7265146, Sep 4, 2007

Filed:

Apr 20, 2005

Appl. No.:

11/111105

Inventors:

Dean R. Artis - Kensington CA, US
David Y. Jackson - San Bruno CA, US
Thomas E. Rawson - Mountain View CA, US
Mark E. Reynolds - Millbrae CA, US
Daniel P. Sutherlin - South San Francisco CA, US
Mark S. Stanley - Pacifica CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 31/403
C07D 207/04
C07D 209/82

US Classification:

514411, 548427, 548439, 548440, 548444, 548530, 548537, 548538, 514408, 514423

Abstract:

Provided are compounds of formula (I).

US Patent:

7888364, Feb 15, 2011

Filed:

Sep 2, 2005

Appl. No.:

11/217663

Inventors:

Janet L. Gunzner - Berkeley CA, US
Daniel Sutherlin - South San Francisco CA, US
Mark S. Stanley - Pacifica CA, US
Liang Bao - San Mateo CA, US
Georgette M. Castanedo - Redwood City CA, US
Rebecca L. Lalonde - Berkeley CA, US
Shumei Wang - Foster City CA, US
Mark E. Reynolds - Millbrae CA, US
Scott J. Savage - Burlingame CA, US
Kimberly Malesky - San Francisco CA, US
Michael S. Dina - Daly City CA, US

Assignee:

Curis, Inc. - Cambridge MA

International Classification:

C07D 403/02
A61K 31/4439

US Classification:

51425505, 514332, 514338, 514339, 514341, 544333, 546256, 5462684, 5462721, 5462754

Abstract:

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:.

US Patent:

7893072, Feb 22, 2011

Filed:

Jul 2, 2004

Appl. No.:

10/884379

Inventors:

Mark Reynolds - Millbrae CA, US
Paul Polakis - Burlingame CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A01N 43/54
A01N 43/42
A61K 31/58

US Classification:

514269, 514284, 514176

Abstract:

Compounds of the disclosure provide compositions, which are effective for prophylaxis and treatment of diseases or disorders, such as cell-proliferation, angiogenesis, or apoptosis mediated diseases. The disclosure encompasses compounds, analogs, prodrugs, metabolites, and pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer, tumors, and like conditions. The disclosure also provides therapeutic methods including the administration of an effective amount of a compound of the disclosure.